FDA action counts
| Total FDA actions | 1 |
|---|---|
| Warning letters | 0 |
| Recalls | 0 |
| Approval records | 1 |
| Form 483 inspection citations | 0 |
| Most recent action | September 23, 2026 |
Enforcement history
On 2026-09-23, Argus HQ recorded an FDA approval for ELEVAR THERAPEUTICS INC, rated "info" severity in Argus HQ's classification: ELEVAR THERAPEUTICS INC — NDA approval: LYRFIGTU (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.
Risk pattern analysis
Argus HQ analysis — not an FDA finding
This section is Argus HQ analysis, not an FDA finding. ELEVAR THERAPEUTICS INC has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Frequently asked questions
- What is the most recent FDA action against ELEVAR THERAPEUTICS INC?
- The most recent FDA event Argus HQ has on file for ELEVAR THERAPEUTICS INC is dated 2026-09-23, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
- Does Argus HQ track new FDA actions for ELEVAR THERAPEUTICS INC automatically?
- Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to ELEVAR THERAPEUTICS INC is observed, this page's event count and history update automatically.
- How many FDA actions does Argus HQ track for ELEVAR THERAPEUTICS INC?
- 1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.
- What is the most recent FDA action on file for ELEVAR THERAPEUTICS INC?
- September 23, 2026. Argus HQ ingests new FDA enforcement records daily.
Every FDA action tied to this company, the week it happens.
Free weekly briefing. Real-time alerts on paid plans.
Related enforcement actions
Compare with
Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Verified from FDA.gov · Last updated: Sep 23, 2026Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). ELEVAR THERAPEUTICS INC — FDA Enforcement History. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/elevar-therapeutics-inc
"ELEVAR THERAPEUTICS INC — FDA Enforcement History." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/elevar-therapeutics-inc.
Argus HQ Research. "ELEVAR THERAPEUTICS INC — FDA Enforcement History." Digital Empire Holdings LLC. Accessed October 12, 2026. https://argushq.ai/company/elevar-therapeutics-inc.
@misc{argushq_argushq_ai_company_elevar_therapeutics_inc_2026,
title = {ELEVAR THERAPEUTICS INC — FDA Enforcement History},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/company/elevar-therapeutics-inc},
note = {Accessed: October 12, 2026}
}Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗